Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment).
货号（Catalog No.）
CSD00162
通用名INN
Tucotuzumab Celmoleukin
纯度(Purity)
>95%
浓度( Concentration)
1mg/ml
Formulation
PBS buffer pH7.5
Source
CHO cells
内毒素(Endotoxin level)
Please contact with the lab for this information.
生物活性
产品描述(Description)
Tucotuzumab celmoleukin is under investigation in clinical trial NCT00016237 (Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment).
别名(Alternative names)
EMD 273066,KSA-Interleukin-2,huKS-IL2,huKS1/4-IL-2
靶点;物种(Specificity target name;species)
EPCAM/CD326[Homo sapiens]
种类(Species)
Humanized
受体鉴定(Receptor identification)
IgG1-nd
化学信息
CAS
339986-90-2
存储条件(Storage)
store at -80°C
Note
For research use only. Not suitable for clinical or therapeutic use.
...
产品展厅
